ArticleInternational journal of hematology2024

Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma.

Kenta Hayashino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.